In contrast to most human cancers, p53 mutations are rare in testicular tumors, and this lack of p53 mutations is the reason for the better therapeutic response to therapy, due to the sensitivity of testicular tumors against Cisplatin [205]. This evidence concerns the gene TP53 and cancer.